[go: up one dir, main page]

PL1940366T3 - Miękkie, zawierające chlorowodorek palonosetronu kapsułki o zwiększonej stabilności i biodostępności - Google Patents

Miękkie, zawierające chlorowodorek palonosetronu kapsułki o zwiększonej stabilności i biodostępności

Info

Publication number
PL1940366T3
PL1940366T3 PL07819163T PL07819163T PL1940366T3 PL 1940366 T3 PL1940366 T3 PL 1940366T3 PL 07819163 T PL07819163 T PL 07819163T PL 07819163 T PL07819163 T PL 07819163T PL 1940366 T3 PL1940366 T3 PL 1940366T3
Authority
PL
Poland
Prior art keywords
bioavailability
improved stability
soft capsules
palonosetron hydrochloride
palonosetron
Prior art date
Application number
PL07819163T
Other languages
English (en)
Inventor
Daniele Bonadeo
Giorgio Calderari
Enrico Braglia
Riccardo Braglia
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1940366(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of PL1940366T3 publication Critical patent/PL1940366T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07819163T 2006-10-24 2007-10-19 Miękkie, zawierające chlorowodorek palonosetronu kapsułki o zwiększonej stabilności i biodostępności PL1940366T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85434206P 2006-10-24 2006-10-24
EP07819163A EP1940366B9 (en) 2006-10-24 2007-10-19 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
PCT/EP2007/009098 WO2008049552A1 (en) 2006-10-24 2007-10-19 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Publications (1)

Publication Number Publication Date
PL1940366T3 true PL1940366T3 (pl) 2009-09-30

Family

ID=38921772

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07819163T PL1940366T3 (pl) 2006-10-24 2007-10-19 Miękkie, zawierające chlorowodorek palonosetronu kapsułki o zwiększonej stabilności i biodostępności

Country Status (35)

Country Link
US (2) US20080152704A1 (pl)
EP (1) EP1940366B9 (pl)
JP (1) JP5144527B2 (pl)
KR (1) KR101441459B1 (pl)
CN (1) CN101573106B (pl)
AR (1) AR063362A1 (pl)
AT (1) ATE427742T1 (pl)
AU (1) AU2007308378B2 (pl)
BR (1) BRPI0718497B1 (pl)
CA (1) CA2666512C (pl)
CL (1) CL2007003055A1 (pl)
CO (1) CO6160289A2 (pl)
CR (1) CR10728A (pl)
CY (1) CY1109914T1 (pl)
DE (1) DE602007000856D1 (pl)
DK (1) DK1940366T3 (pl)
EA (1) EA016455B1 (pl)
ES (1) ES2325339T3 (pl)
GT (1) GT200900096A (pl)
HN (1) HN2009000785A (pl)
HR (1) HRP20090341T1 (pl)
IL (1) IL198225A (pl)
ME (1) ME01949B (pl)
MX (1) MX2009004461A (pl)
NO (1) NO342353B1 (pl)
NZ (1) NZ576237A (pl)
PL (1) PL1940366T3 (pl)
PT (1) PT1940366E (pl)
RS (1) RS50842B (pl)
SI (1) SI1940366T1 (pl)
SV (1) SV2009003238A (pl)
TW (1) TWI367212B (pl)
UA (1) UA97653C2 (pl)
WO (1) WO2008049552A1 (pl)
ZA (1) ZA200902773B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ569984A (en) * 2006-01-27 2011-06-30 Eurand Inc Drug delivery systems comprising weakly basic drugs and organic acids
CA2640460C (en) * 2006-01-27 2015-05-26 Eurand, Inc Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
WO2010077669A2 (en) 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
US20120253046A1 (en) * 2009-11-13 2012-10-04 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
CN107050455B (zh) 2009-11-18 2020-09-29 赫尔森保健股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
HUE030811T2 (hu) 2011-10-18 2017-05-29 Helsinn Healthcare Sa Netupitant és palonosetron terápiás kombinációi
CN103446072A (zh) * 2012-06-02 2013-12-18 正大天晴药业集团股份有限公司 帕洛诺司琼的固体药物组合物
US20160287524A1 (en) * 2013-03-19 2016-10-06 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9877959B2 (en) 2013-12-23 2018-01-30 Samyang Biopharmaceuticals Corporation Pharmaceutical composition containing palonosetron
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN111205283A (zh) * 2020-01-20 2020-05-29 广州九植医药科技有限公司 一种盐酸帕洛诺司琼有关物质b的合成方法
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4633608A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
CN120693151A (zh) 2022-12-12 2025-09-23 阿尔弗雷德.E.蒂芬巴赫尔有限责任两合公司 包括奈妥匹坦和帕洛诺司琼的固定剂量组合

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US4182914A (en) * 1974-01-22 1980-01-08 Nippon Oil Company Limited Process for continuously producing diisopropyl ether
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
EP0200444B1 (en) * 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
ZA909529B (en) * 1989-11-28 1992-08-26 Syntex Inc New tricyclic compounds
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2823118B1 (fr) * 2001-04-04 2004-03-19 Lavipharm Lab Inc Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
CA2505990C (en) 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents

Also Published As

Publication number Publication date
MX2009004461A (es) 2009-09-16
RS50842B (sr) 2010-08-31
IL198225A0 (en) 2009-12-24
EP1940366B1 (en) 2009-04-08
SI1940366T1 (sl) 2009-08-31
NO20091945L (no) 2009-05-25
KR20090073234A (ko) 2009-07-02
HK1117769A1 (en) 2009-01-23
HN2009000785A (es) 2011-10-14
ES2325339T3 (es) 2009-09-01
WO2008049552A1 (en) 2008-05-02
EP1940366A1 (en) 2008-07-09
NO342353B1 (no) 2018-05-07
HRP20090341T1 (hr) 2009-07-31
CA2666512A1 (en) 2008-05-02
DK1940366T3 (da) 2009-06-29
EA016455B1 (ru) 2012-05-30
CY1109914T1 (el) 2014-09-10
CA2666512C (en) 2014-05-27
US20170035748A1 (en) 2017-02-09
PT1940366E (pt) 2009-06-17
AU2007308378B2 (en) 2013-02-21
US20080152704A1 (en) 2008-06-26
TW200827355A (en) 2008-07-01
BRPI0718497B1 (pt) 2024-02-06
JP5144527B2 (ja) 2013-02-13
EA200970396A1 (ru) 2009-10-30
NZ576237A (en) 2011-12-22
GT200900096A (es) 2011-08-29
UA97653C2 (ru) 2012-03-12
IL198225A (en) 2013-03-24
EP1940366B9 (en) 2009-12-02
TWI367212B (en) 2012-07-01
CN101573106B (zh) 2013-07-24
AU2007308378A1 (en) 2008-05-02
AR063362A1 (es) 2009-01-21
ZA200902773B (en) 2010-03-31
KR101441459B1 (ko) 2014-09-18
ME01949B (me) 2010-08-31
CL2007003055A1 (es) 2008-03-24
SV2009003238A (es) 2009-11-09
CR10728A (es) 2009-07-23
BRPI0718497A2 (pt) 2014-07-08
ATE427742T1 (de) 2009-04-15
CN101573106A (zh) 2009-11-04
CO6160289A2 (es) 2010-05-20
JP2009507933A (ja) 2009-02-26
DE602007000856D1 (de) 2009-05-20

Similar Documents

Publication Publication Date Title
ZA200902773B (en) Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
ZA200901464B (en) Packaging comprising pharmaceutical forms
ZA200810790B (en) Stable laquinimod preparations
ZA201000831B (en) Solid preparation comprising alogliptin and metformin hydrochloride
IL189781A0 (en) Sulphonylpyrrole hydrochloride salts and pharmaceutical compositions containing the same
IL194751A0 (en) Drugs and uses
IL193700A0 (en) Medicaments and proteins
IL206479A0 (en) Crystalline forms of palonosetron hydrochloride
IL219963A (en) Pharmaceutical composition containing transcorsorcaline hydrochloride and mannitol and its use
GB0606234D0 (en) Pharmaceutically acceptable salts and polymorphic forms
IL179331A0 (en) Preparation of levalbuterol hydrochloride
IL195618A0 (en) Drug administration methods
GB0613928D0 (en) Pharmaceutically acceptable salt and polymorphic forms
GB0411032D0 (en) Capsules
PL1934388T3 (pl) Sposób projektowania leków
GB0605344D0 (en) Pharmaceutically acceptable salts and polymorphic forms
ZA200904360B (en) Methods and formulations for improved bioavailability of antiprogestins
HU0600097D0 (en) Pharmaceutical composition comprising tacrolimus
TWI368305B (en) Bump structures and packaged structures thereof
EP1744745A4 (en) PHARMACEUTICAL NITRON
GB0609465D0 (en) Pharmaceutically acceptable salts and polymorphic forms
IL185561A0 (en) Microject devices and methods for drug delivery
GB0613761D0 (en) A pharmaceutical formulation and method for the preparation thereof
GB0613927D0 (en) Pharmaceutically acceptable salt and polymorphic forms
GB0523695D0 (en) Capsule